G1 Therapeutics falls on plans to discontinue cancer drug study

G1 Therapeutics

13/02/2023 12:00

** Shares of G1 Therapeutics Inc  GTHX.O  fall 39.6% to
$4.31 premarket
    ** Company says it has decided to discontinue a late-stage
study testing trilaciclib, in combination with two other drugs,
for the treatment of a type of colon cancer
    ** Placebo outperformed the drug in early anti-tumor
efficacy data, including overall response rate, or percentage of
patients whose cancer shrinks or disappears after treatment, and
preliminary measures of survival - GTHX
    ** The study was designed to evaluate efficacy and safety of
the drug administered in addition to triplet therapy with the
first-line therapy in patients with advanced colorectal cancer,
says GTHX
    ** Up to last close, stock fell ~31.6% in the past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com))